

## **Supplementary Information**

### **Human Retinal Organoid Model of Disease-Relevant Photoreceptor Cell Death Amenable to Drug Screening**


Shama Parween, Anthony J. Saviola, Anna C. Howell, Stefanie Varghese, David Ceja Galindo, and M. Natalia Vergara

#### **Contents:**


- Figure S1 and legend: Confocal images and corresponding quantification of Day 180 human ROs treated with CSE 500 µg/ml for 5 days, assessing photoreceptor and cell death markers.
- Figure S2 and legend: Proteomic analysis of ROs treated with CSE 750 µg/ml for 48 h.
- Tables S1 and S2: Lists of primary and secondary antibodies used for immunofluorescence studies.

**Figure S1. Apoptosis induction in CSE-treated ROs**

**S.1A**



**S.1B**




ROs were treated with vehicle control (DMSO) or CSE-500 µg/ml for 5 days to evaluate the extent of apoptotic cell death:

- A. A representative confocal micrographs of D180 RO sections stained with TUNEL to examine DNA fragmentation, along with recoverin (REC) staining to identify photoreceptor cells. Scale bar: 100µm. TUNEL staining quantification shows a statistically significant increase in cell death in CSE-treated ROs compared to vehicle controls (DMSO). Relative TUNEL (+) area: DMSO: 1.342±0.28 (n=8), and CSE-500 µg/ml: 9.501±0.988 (n=8). Error bars indicate Mean±SEM; T-test; \*\*\*\*p<0.0001.
- B. Immunofluorescence staining was performed on D180 RO sections using antibodies for CLC3 and photoreceptor markers NRL (Rod) and RXR-γ (Cone). Colocalization of CLC3 and photoreceptor markers was also analyzed. Scale bar: 100µm. Bar graph represents the quantification of relative CLC-3-labeled area/DAPI. A significant increase in CLC3-mediated

photoreceptor cell death was observed in CSE-treated ROs compared to vehicle controls (DMSO). DMSO=  $5.483 \pm 0.95$  (n=5), and CSE-500  $\mu\text{g/ml}$ =  $19.622 \pm 3.599$  (n=5). Error bar shows Mean $\pm$ SEM; T-test; \*\*p<0.005.

Figure S2. Proteomic analysis of ROs treated with CSE-750 µg/ml or DMSO for 48 h



LC-MS proteomic analysis of ROs treated with CSE-750 µg/ml show very similar results to those observed in ROs treated with CSE-500 µg/ml, along with several additional DEPs.

A. Heatmap and hierarchical clustering representation of the top 50 DEPs across three independent hiPSC cell lines (ILC67.3, ILC62.6, and CB6.2), comparing DMSO and CSE-

750 µg/ml treatments. Each column represents an individual sample, and clustering reflects distinct proteomic signatures induced by CSE exposure.

- B. Volcano plot illustrating differential protein expression between CSE (750 µg/mL) and vehicle (DMSO) control-treated ROs. The x-axis represents the log<sub>2</sub> fold change (log<sub>2</sub>FC), and the y-axis represents the statistical significance (−log<sub>10</sub> p-value). A total of 80 significant proteins (Fold Change ≥ 1.4, p < 0.05) were plotted. Black dots indicate non-significant changes; blue and red dots indicate significantly downregulated and upregulated proteins, respectively.
- C. KEGG pathway enrichment analysis of DEPs revealed significant enrichment in pathways associated with ferroptosis, metabolic pathways, neurodegeneration, and others in CSE-treated ROs compared to vehicle (DMSO) control-treated ROs.
- D. Gene Ontology (GO) Biological Process analysis identified key functional categories significantly associated with DEPs in CSE-treated ROs, highlighting pathways involved in autophagy, mRNA processing, and cellular processes.
- E. GO Molecular Function analysis revealed enrichment in molecular activities such as antioxidant activity, receptor binding, and protein transport among the DEPs following CSE exposure.

**Table S1.** Primary Antibody Information

Primary antibody	Company/State/Country	Catalog Number	Dilution
Recoverin	Millipore, Burlington, MA, USA	AB5585	1:1000
Human NRL	R&D Systems; NE, Minneapolis, MN, USA.	AF2945	1:300
RXR- $\gamma$ (A-2)	Santa Cruz, CA, USA	Sc-365252	1:100
Cleaved Caspase 3 (Asp175)	Cell Signaling Technology; Danvers, MA, USA	9664	1:500
Cleaved Caspase 9 (Asp330)	Cell Signaling Technology; Danvers, MA, USA	7237	1:500

**Table S2. Secondary Antibody information**

<b>Secondary antibody</b>	<b>Company</b>	<b>Catalog Number</b>	<b>Dilution</b>
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 594	Thermo Fisher Scientific; Waltham, MA, USA	A21207	1:2000
Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 594	Thermo Fisher Scientific; Waltham, MA, USA	A21203	1:2000
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488	Thermo Fisher Scientific; Waltham, MA, USA	A21206	1:2000
Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488	Thermo Fisher Scientific; Waltham, MA, USA	A32766	1:2000
Donkey anti-Goat IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647	Thermo Fisher Scientific; Waltham, MA, USA	A21447	1:2000